Search for: "Ariad Pharmaceuticals Inc." Results 41 - 60 of 103
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
7 Dec 2009, 7:51 am by Matt Osenga
This afternoon, the 11 active judges of the Federal Circuit will hear argument in Ariad Pharmaceuticals, Inc. v. [read post]
10 Oct 2016, 12:40 pm by Tom Lamb
Sprycel (dasatinib) -- Bristol-Myers Squibb Canada Iclusig (ponatinib hydrochloride) -- ARIAD Pharmaceuticals, Inc. [read post]
28 May 2013, 10:51 am by Lawrence B. Ebert
From Ex parte GillisAs to written description:“[T]he written description requirement does not demand eitherexamples or an actual reduction to practice; a constructive reduction topractice that in a definite way identifies the claimed invention can satisfy thewritten description requirement” Ariad Pharmaceuticals, Inc. v. [read post]
1 Dec 2017, 11:35 am by Nate Nead
Bard in Q2 2017 helped increase the value of deals.[27] Takeda Pharmaceutical Company acquired ARIAD Pharmaceuticals Inc for $5.2 billion to expand its oncology business. [read post]
26 Feb 2014, 5:37 pm
  Procedural HistoryPlaintiff GlaxoSmithKline LLC (“GSK”) sued Banner Pharmacaps, Inc., Impax Laboratories, Inc., Roxane Laboratories, Inc., Mylan Inc., Mylan Pharmaceuticals, Inc., and Watson Laboratories, Inc. [read post]
26 Mar 2010, 4:15 am by admin
Court of Appeals for the Federal Circuit confirmed March 22 that Section 112 of the Patent Act contains a separate written description requirement beyond the requirement that a patent’s claims be enabled in the specification (Ariad Pharmaceuticals Inc. v. [read post]
1 Sep 2010, 4:46 pm by Dennis Crouch
Eon Labs, Inc. and Elan Pharmaceuticals, Inc. at http://www.patentlyo.com/patent/2010/08/ignoring-non-patentable-elements-while-judging-novelty.html Hyatt v. [read post]
1 Apr 2013, 9:11 pm by Dennis Crouch
Cir. 1996) Ariad Pharmaceuticals, Inc. v. [read post]